These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15884402)

  • 1. [Pneumococcal vaccination; arguments for informing parents about the options available].
    Beaujean DJ; Verweij MF; van Steenbergen JE
    Ned Tijdschr Geneeskd; 2005 Apr; 149(17):909-11. PubMed ID: 15884402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serious invasive pneumococcal disease in young children: the importance of vaccination].
    Haveman LM; Geelen SP; Sanders EA; Wolfs TF
    Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1917-20. PubMed ID: 12404904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Universal vaccination against group-C meningococci and pneumococci; summary of the advice from the Health Counsil of the Netherlands].
    Ruitenberg EJ; Houweling H
    Ned Tijdschr Geneeskd; 2002 May; 146(20):938-40. PubMed ID: 12051061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
    Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
    Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Universal vaccination against group C meningococci and pneumococci; advice from the Health Council of the Netherlands].
    van Furth AM; Vandenbroucke-Grauls CM
    Ned Tijdschr Geneeskd; 2002 May; 146(20):932-3. PubMed ID: 12051059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
    Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
    Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antipneumococcal vaccine: up date and prospective].
    Caramia G; Pastorelli G
    Minerva Pediatr; 2005 Oct; 57(5):229-41. PubMed ID: 16205607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pneumococcal vaccination; arguments for informing parents about the options available].
    van Furth AM; Vermeulen RJ; Plötz FB
    Ned Tijdschr Geneeskd; 2005 Sep; 149(36):2024-5. PubMed ID: 16171119
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The debate in Italy and in Europe about the adoption of pneumococcal vaccine in children].
    Maida A
    Ann Ig; 2002; 14(6 Suppl 7):1-5. PubMed ID: 12638358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
    de Greeff SC; Sanders EA; de Melker HE; van der Ende A; Vermeer PE; Schouls LM
    Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1454-7. PubMed ID: 17633974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
    Silfverdal SA; Berg S; Hemlin C; Jokinen I
    Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Missing spleen: indication for pneumococcal vaccination].
    van Dijk GW; van Leeuwen HJ; van Gijn J; Hoepelman IM
    Ned Tijdschr Geneeskd; 2003 Mar; 147(10):425-8. PubMed ID: 12666509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
    Ortqvist A; Jönsson B; Baltussen R; Ament A
    Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pneumococcal vaccination for persons 65 years of age and older].
    van den Bosch WJ
    Ned Tijdschr Geneeskd; 2002 May; 146(18):838-9. PubMed ID: 12038219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dutch Health Council advice 'Vaccination against pneumococcal infections in elderly persons and immunocompromised adults'].
    Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 May; 148(18):871-4. PubMed ID: 15152387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases.
    Rendi-Wagner P; Paulke-Korinek M; Kundi M; Burgmann H; Georgopoulos A; Vécsei A; Kollaritsch H
    Vaccine; 2009 Jun; 27(30):3963-8. PubMed ID: 19393711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.